Bologna (Italy), 4 November 2016.
Cellply announced today that the results of a scientific collaboration with hematologists at Seragnoli Institute of Sant’Orsola Polyclinic in Bologna (Italy) working on Acute Myeloid Leukemia (AML), a group led by Prof. Giovanni Martinelli, will be presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH), on December 3-6 in San Diego, CA, USA. “This is a key milestone for our company as it shows the potential of the Open Microwell technology and the IVD platform under development at Cellply to become an important tool for guiding the identification of the appropriate treatment for each patient or patient set through the analysis of biological information that today remain mostly not exploited for patient stratification”, says Massimo Bocchi, CEO of Cellply. “The preliminary data collected within this scientific activity provided good correlation between our test and the clinical outcome, making Cellply’s platform promising for predicting the haematological response, an endpoint of primary importance not only from a clinical standpoint but also for its use within clinical trials”, added Laura Rocchi, Head of Biology at Cellply. The following abstract was accepted for poster presentation by the American Society of Hematology.
Title: Ex-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform
Authors: Laura Rocchi, Andrea Faenza, Laura Rambelli, Viviana Guadagnuolo, Giovanni Marconi, Giorgia Simonetti, Cristina Papayannidis, Antonella Padella, Nicola Pecorari, Luca Giulianelli, Dario Biscarini, Giovanni Martinelli, Roberto Guerrieri and Massimo Bocchi
Abstract ID: 1675
Date/Time: Saturday, December 3, 2016, 5:30 PM-7:30 PM
Location: Hall GH (San Diego Convention Center)
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I
Link to abstract on Blood Journal